The University of Oxford and the Serum Institute of India (SII) have solidified a crucial partnership aimed at developing a novel, multi-stage malaria vaccine, marking a significant advancement in the ongoing global effort to combat the devastating disease. This collaboration, formalized through a license agreement between Oxford University Innovation (OUI) and the world’s largest vaccine manufacturer by volume, is designed to accelerate the development and large-scale production of a promising vaccine candidate known as R78C. The pact builds upon a history of successful cooperation between the two institutions in the field of malaria vaccine research, with the overarching goal of improving health outcomes for millions worldwide.
Simon Draper, Professor of Vaccinology and Translational Medicine in the Department of Paediatrics at Oxford University, emphasized the importance of this new agreement, stating, “This agreement marks an important milestone in our efforts to develop a highly effective multi-stage malaria vaccine.” He further elaborated on the scientific approach, explaining that the vaccine aims to target different stages of the malaria parasite’s lifecycle by incorporating multiple antigens. This strategy is intended to elicit a stronger and more enduring immune response, offering enhanced protection against the disease. Information reaching TahirRihat.com suggests that the collaboration with the Serum Institute of India is considered indispensable for ensuring that, should the vaccine prove successful, it can be manufactured at the necessary scale and made readily accessible to the populations most vulnerable to malaria.
The R78C vaccine candidate is specifically designed to target blood-stage antigens of Plasmodium falciparum, a primary cause of severe malaria, namely RIPR and CyPRA. The University of Oxford has indicated that this new licensing arrangement will empower the Serum Institute of India to support the ongoing development, facilitate large-scale manufacturing, and potentially lead to the future commercialization of the multi-stage vaccine. This comprehensive support is expected to significantly expedite the vaccine’s progression towards clinical evaluation, a critical step in its journey from laboratory research to public health intervention. The commitment from both institutions underscores the urgent need for sustained scientific innovation in malaria prevention, particularly as research increasingly focuses on vaccines capable of intervening at various points in the parasite’s complex life cycle.
Dr Umesh Shaligram, Executive Director at the Serum Institute of India, echoed the sentiment of progress and accessibility, noting, “Malaria prevention continues to demand sustained scientific innovation, especially as efforts move towards vaccines that can target the parasite at different stages of its lifecycle.” He reiterated SII’s consistent dedication to advancing such innovative approaches with the explicit aim of making them both effective and affordable. Dr Shaligram highlighted that the agreement with Oxford University for the development of R78C is a natural extension of their existing collaboration and reinforces their commitment to the development of next-generation malaria vaccine candidates. As a company within the Cyrus Poonawalla group, SII’s partnership with the esteemed UK university has consistently prioritized equitable access to vaccines, with a particular focus on low and middle-income countries. The strategic intent behind this partnership is to leverage the Serum Institute of India’s extensive global manufacturing capabilities to ensure that any successful malaria vaccine candidates can be produced affordably and supplied efficiently to regions where malaria is endemic.
Dr Matthew Carpenter, OUI’s Deputy Head of Licensing and Ventures for Life Sciences, further underscored the significance of the licensing agreement, describing it as a pivotal moment in the development of a multi-stage malaria vaccine. He pointed out that this pact enables the integration of the R78C candidate alongside other existing vaccine components, representing a sophisticated approach to vaccine design. Dr Carpenter also highlighted how Oxford’s research prowess is being translated into tangible global health solutions, effectively merging cutting-edge scientific innovation with robust manufacturing expertise to accelerate the creation of vaccines for those most affected by malaria. This initiative is part of a broader network of collaborations dedicated to advancing novel malaria vaccines. In a related development, SII has also entered into an agreement with ExpreS2ion, securing access to its proprietary ExpreS2 expression platform. This platform has already played a role in the clinical-stage production of vaccine components such as RH5.1 and R78C, further strengthening the technological foundation for this new vaccine candidate. The University of Oxford has consistently pointed out that malaria remains a formidable global health challenge, with hundreds of millions of cases reported annually, disproportionately affecting children in sub-Saharan Africa. The development of more effective vaccines is widely recognized as a cornerstone of long-term malaria control and eradication strategies, making this partnership a critical step forward.
Tahir Rihat (also known as Tahir Bilal) is an independent journalist, activist, and digital media professional from the Chenab Valley of Jammu and Kashmir, India. He is best known for his work as the Online Editor at The Chenab Times.
